News
MEDP
530.35
-2.16%
-11.69
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Medpace Holdings (MEDP)
TipRanks · 2h ago
Analysts Offer Insights on Healthcare Companies: Medpace Holdings (MEDP) and Molina Healthcare (MOH)
TipRanks · 4h ago
Medpace Holdings: Great Quarter, Stale Backlog, Full Valuation
Seeking Alpha · 8h ago
Medpace Holdings, Inc. Q4 Income Advances, Beats Estimates
NASDAQ · 9h ago
Closing Bell Movers: Upwork down over 20% on soft guidance
TipRanks · 12h ago
*Medpace Holdings Sees 2026 EPS $16.68-EPS $17.50 >MEDP
Dow Jones · 14h ago
*Medpace Holdings Sees 2026 Rev $2.755B-$2.855B >MEDP
Dow Jones · 14h ago
Medpace reports Q4 EPS $4.67, consensus $4.23
TipRanks · 14h ago
Medpace sees FY26 EPS $16.68-$17.50, consensus $16.51
TipRanks · 14h ago
Medpace Q4 revenue beats expectations
Reuters · 14h ago
Medpace Hldgs: Q4 Earnings Insights
Benzinga · 15h ago
Medpace Hldgs Sees FY2026 GAAP EPS $16.68-$17.50 vs $16.48 Est; Sees Sales $2.755B-$2.855B vs $2.812B Est
Benzinga · 15h ago
Medpace Hldgs Q4 EPS $4.67 Beats $4.18 Estimate, Sales $708.450M Beat $689.404M Estimate
Benzinga · 15h ago
MEDPACE HOLDINGS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
Reuters · 15h ago
*Medpace Holdings 4Q Rev $708.5M >MEDP
Dow Jones · 15h ago
*Medpace Holdings 4Q Net $135.1M >MEDP
Dow Jones · 15h ago
Press Release: Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results
Dow Jones · 15h ago
Press Release: Medpace Holdings, Inc. Reports -3-
Dow Jones · 15h ago
*Medpace Holdings 4Q EPS $4.67 >MEDP
Dow Jones · 15h ago
U.S. Earnings Preview: After Market Close Feb. 9
Dow Jones · 15h ago
More
Webull provides a variety of real-time MEDP stock news. You can receive the latest news about Medpace Holdings through multiple platforms. This information may help you make smarter investment decisions.
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.